Target Name: MRTFA
NCBI ID: G57591
Review Report on MRTFA Target / Biomarker Content of Review Report on MRTFA Target / Biomarker
MRTFA
Other Name(s): megakaryocytic acute leukemia protein | MKL | OTTHUMP00000199245 | MRTFA_HUMAN | MKL/myocardin-like protein 1 | Basic, SAP and coiled-coil domain | RNA-binding motif protein 15/megakaryoblastic leukemia-1 fusion protein | Myocardin-related transcription factor A | megakaryoblastic leukemia (translocation) 1 | myocardin related transcription factor A | OTTHUMP00000199246 | Megakaryocytic acute leukemia protein | OTTHUMP00000199247 | MRTF-A | alternative protein MKL1 | BSAC | Myocardin-related transcription factor A isoform 5 | Megakaryoblastic leukemia 1 protein | Megakaryoblastic leukemia 1 | basic, SAP and coiled-coil domain | Megakaryocytic acute leukemia | KIAA1438 | Myocardin related transcription factor A, transcript variant 1 | MKL1 | megakaryoblastic leukemia 1 protein | RBM15/MKL1 fusion | MAL | MRTFA variant 1

Potential MRTFA-based Therapies for Acute Leukemia

MRTFA, or megakaryocytic acute leukemia protein, is a protein that is expressed in the blood cells of individuals with acute leukemia. It is a type of white blood cell that is responsible for carrying oxygen throughout the body. MRTFA has been identified as a potential drug target or biomarker for the treatment of acute leukemia.

Acute leukemia is a type of cancer that affects the bone marrow and blood cells. It is characterized by the rapid growth of white blood cells, which do not function properly and can accumulate in the bone marrow, leading to the formation of leukemia. Treatment for acute leukemia typically involves chemotherapy, radiation therapy, and/or bone marrow transplantation. However, these treatments can have a significant impact on the health and quality of life of patients.

One potential approach to treating acute leukemia is to target MRTFA, which is a protein that is expressed in the blood cells of individuals with acute leukemia. MRTFA is a type of glycoprotein that is made up of a protein and a sugar molecule. It is expressed in the blood cells of individuals with acute leukemia and has been shown to be associated with the development and progression of acute leukemia.

In addition to its potential as a drug target, MRTFA is also a potential biomarker for the treatment of acute leukemia. MRTFA has been shown to be expressed in the blood cells of individuals with acute leukemia, and it has been used as a marker for the disease in various studies. This suggests that it may be a useful tool for the diagnosis and treatment of acute leukemia.

One potential way to use MRTFA as a drug target is to target the protein itself. This can be done through various techniques, such as inhibiting the activity of MRTFA or using antibodies to target the protein. By blocking the activity of MRTFA, it may be possible to reduce the growth of leukemia cells and potentially lead to the diagnosis and treatment of acute leukemia.

Another potential approach to using MRTFA as a drug target is to use it as a biomarker to predict the response to treatment. By analyzing the levels of MRTFA in the blood cells of individuals with acute leukemia before and after treatment, it may be possible to determine whether treatment is effective and identify potential biomarkers for the disease.

In conclusion, MRTFA is a protein that is expressed in the blood cells of individuals with acute leukemia. It has been identified as a potential drug target or biomarker for the treatment of acute leukemia, and further research is needed to determine its potential utility in this field.

Protein Name: Myocardin Related Transcription Factor A

Functions: Transcription coactivator that associates with the serum response factor (SRF) transcription factor to control expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration (PubMed:26224645). The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. MRTFA binds G-actin via its RPEL repeats, regulating activity of the MRTFA-SRF complex. Activity is also regulated by filamentous actin (F-actin) in the nucleus

The "MRTFA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRTFA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MRTFB | MRTO4 | MS4A1 | MS4A10 | MS4A12 | MS4A13 | MS4A14 | MS4A15 | MS4A18 | MS4A2 | MS4A3 | MS4A4A | MS4A4E | MS4A5 | MS4A6A | MS4A6E | MS4A7 | MS4A8 | MSANTD1 | MSANTD2 | MSANTD3 | MSANTD4 | MSC | MSC-AS1 | MSGN1 | MSH2 | MSH3 | MSH4 | MSH5 | MSH5-SAPCD1 | MSH6 | MSI1 | MSI2 | MSL1 | MSL2 | MSL3 | MSL3P1 | MSLN | MSLNL | MSMB | MSMO1 | MSMP | MSN | MSNP1 | MSR1 | MSRA | MSRA-DT | MSRB1 | MSRB1P1 | MSRB2 | MSRB3 | MSRB3-AS1 | MSS51 | MST1 | MST1L | MST1P2 | MST1R | MSTN | MSTO1 | MSTO2P | MSX1 | MSX2 | MSX2P1 | MT1A | MT1B | MT1DP | MT1E | MT1F | MT1G | MT1H | MT1HL1 | MT1IP | MT1JP | MT1L | MT1M | MT1P1 | MT1P3 | MT1X | MT1XP1 | MT2A | MT3 | MT4 | MTA1 | MTA1-DT | MTA2 | MTA3 | MTAP | MTARC1 | MTARC2 | MTATP6P1 | MTATP8P1 | MTBP | MTCH1 | MTCH2 | MTCL1 | MTCO1P1 | MTCO1P12 | MTCO1P15 | MTCO2P33 | MTCO3P1